相关实验视频

Updated: Jul 23, 2025

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

新生儿中Gentamicin在新生儿中具有血液动力学显著的专利管道动脉

Kannan Sridharan¹, Abdulraoof Al Madhoob², Muna Al Jufairi^2,3

¹Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.

Journal of pharmacy & bioallied sciences

|July 20, 2023

概括

这项研究发现,患有血液动力学上显著的专利性动脉管 (hsPDA) 的早产新生儿接受了更长的 جنت美辛治疗时间,但在 جنت美辛最低度或动脉管关闭率上没有差异. 根他米辛的使用没有影响hsPDA的关闭.

科学领域:

新生儿心脏病学新生儿心脏病学
药理动力学药理动力学
新生儿药理学新生儿药理学

背景情况:

亨塔米辛可能会导致血管扩张,可能会影响动脉通道 (DA) 关闭.
血液动力学显著的专利动脉管 (hsPDA) 在早产新生儿中很常见.
hsPDA可能会改变 gentamicin 的药理动力学和最低度.

研究的目的:

评估与乙氨基治疗的新生儿中 gentamicin 使用和 hsPDA 关闭之间的关联.
评估hsPDA对 gentamicin 最低度的影响.

主要方法:

对60名患有hsPDA的新生儿和102名没有hsPDA的新生儿进行前性观察研究.
声心成像用于诊断hsPDA和评估DA大小.
记录了亨塔米辛的剂量,持续时间和最低度.

主要成果:

接受hsPDA治疗的新生儿接受了更长的 gentamicin 治疗时间,但每日剂量较低.
两组之间没有发现 gentamicin 最低度的显著差异.
根他米辛的使用与hsPDA关闭无关,但更长的持续时间与成功关闭相关.

结论:

患有hsPDA的新生儿需要更长的 gentamicin 治疗时间.
同时服用珍塔素并没有显著影响hsPDA关闭率.
没有观察到hsPDA对 gentamicin 最低度的显著影响.

关键词:

氨基甘油酸氨基基化物在 PDA 和 PDA 之间.对心血管的影响.这是一种 gentamicin 药物.

更多相关视频

Modified Technique for the Use of Neonatal Murine Hearts in the Langendorff Preparation

Modified Technique for the Use of Neonatal Murine Hearts in the Langendorff Preparation

Published on: March 4, 2022

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

相关概念视频

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...